Calithera Biosciences has enroled the first subject in a Phase II clinical trial of sapanisertib (CB-228) in relapsed/refractory NRF2 (NFE2L2)-mutated squamous non-small cell lung cancer (sqNSCLC) patients.

NRF2 mutations are seen in a substantial sub-population of patients across various kinds of solid tumours. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A potent and selective, dual mTORC 1/2 inhibitor, sapanisertib acts on a crucial survival mechanism in tumours that harbour these mutations. 

The company acquired sapanisertib from Takeda in the fourth quarter of last year.

Earlier, this compound showed single-agent clinical activity in relapsed/refractory NRF2-mutated sqNSCLC patients. 

See Also:

The multicentre, open-label trial will analyse sapanisertib monotherapy in NRF2-mutated sqNSCLC patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

These subjects must have advanced on or following platinum-doublet chemotherapy and immune checkpoint inhibitor therapy (anti-PD-L1) irrespective of anti-CTLA-4.

In the trial, 2mg twice daily or 3mg once daily dose of sapanisertib will be administered in patients with sqNSCLC harbouring either wild-type (WT) or mutated NRF2.

The trial intends to validate sapanisertib’s selective activity in NRF2-mutated tumours versus WT tumours and refine the treatment dose in this biomarker-defined population.

Investigator-evaluated overall response rate (ORR) as per RECIST v1.1 and safety are the trial’s primary endpoints.

Duration of response, progression-free survival and overall survival are included as the secondary endpoints of the trial.

The trial findings would aid the company in commencing a registrational study in biomarker-specific sqNSCLC populations.

Calithera Biosciences president and CEO Susan Molineaux said: “Sapanisertib has the potential to be a first-in-class treatment for patients with NRF2-mutated squamous lung cancer, a patient population with poor prognosis and high unmet need. 

“This study is designed to further validate the NRF2 mutation as a selection biomarker, and we plan to share data from the trial by the first quarter of 2023.”